Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Lindsey George, M.D., attending physician in the Division of Hematology at Children’s Hospital of Philadelphia, and a clinical investigator in the Phase 1/2 clinical trial of SPK-9001 for hemophilia B, will present updated interim data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress in Berlin.

Share this story, choose your platform!